| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
(19R)-13-Deoxy-19-hydroxyenmein is reported to have anti-proliferative activities. The specific molecular targets mediating its anticancer effects have not been fully elucidated in the available literature. However, as an enmein-type diterpene, it likely interacts with cellular pathways involved in cell cycle regulation and apoptosis. Its structural complexity suggests potential interactions with multiple cellular targets, but further studies are needed to identify its primary mechanism of action.
|
|---|---|
| ln Vitro |
In vitro, (19R)-13-Deoxy-19-hydroxyenmein demonstrates significant anti-proliferative activity against a panel of human cancer cell lines. It exhibits IC50 values of 0.41 μM against K562 (chronic myeloid leukemia), 0.85 μM against MGC-803 (gastric cancer), 0.43 μM against CaEs-17 (esophageal cancer), and 1.89 μM against Bel-7402 (hepatocellular carcinoma). These values indicate potent activity, particularly against leukemia and esophageal cancer cell lines, with relatively lower potency against hepatocellular carcinoma cells.
|
| ln Vivo |
Specific in vivo data for (19R)-13-Deoxy-19-hydroxyenmein are not available in the current literature. As an anti-proliferative diterpene derivative with in vitro activity against multiple cancer cell lines, the compound would have potential for in vivo efficacy studies in mouse xenograft models of leukemia, gastric cancer, esophageal cancer, and hepatocellular carcinoma. Further preclinical development would require establishing maximum tolerated doses and evaluating pharmacokinetic properties in animal models.
|
| Enzyme Assay |
The anti-proliferative activity of (19R)-13-Deoxy-19-hydroxyenmein is assessed using standard cell viability assays. Cancer cell lines (K562, MGC-803, CaEs-17, Bel-7402) are cultured in appropriate media and seeded in 96-well plates. Cells are treated with serial dilutions of the compound for 48-72 hours. Cell viability is measured using MTT, CCK-8, or SRB assays. IC50 values are calculated from dose-response curves by non-linear regression analysis.
|
| Cell Assay |
For cellular studies, human cancer cell lines including K562 (leukemia), MGC-803 (gastric), CaEs-17 (esophageal), and Bel-7402 (hepatocellular) are cultured in RPMI-1640 or DMEM supplemented with 10% FBS at 37°C in 5% CO₂. Cells are seeded at appropriate densities and treated with (19R)-13-Deoxy-19-hydroxyenmein at concentrations ranging from 0.01 to 100 μM for 48-72 hours. Cell viability is assessed using MTT or SRB assays, and IC50 values are determined from dose-response curves.
|
| Animal Protocol |
Specific in vivo protocols for (19R)-13-Deoxy-19-hydroxyenmein are not documented in the available literature. For anticancer efficacy studies, standard xenograft models would be employed. Immunodeficient mice would be implanted subcutaneously with cancer cell lines sensitive to the compound (e.g., K562 or MGC-803). Once tumors reach 100-200 mm³, the compound would be administered via intraperitoneal injection or oral gavage at various doses. Tumor volumes would be measured twice weekly, and body weights monitored for toxicity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (19R)-13-Deoxy-19-hydroxyenmein are not reported in the available literature. The compound has a molecular weight of 362.42 g/mol and a molecular formula of C₂₀H₂₆O₆. As a diterpenoid, it is expected to have moderate lipophilicity. Pharmacokinetic studies would be required to determine parameters such as half-life, clearance, volume of distribution, and oral bioavailability in animal models. The compound is typically stored at room temperature.
|
| Toxicity/Toxicokinetics |
Toxicological data for (19R)-13-Deoxy-19-hydroxyenmein are not reported. As a research compound with anti-proliferative activity, it should be handled with appropriate safety precautions. Comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been published. The compound is for research use only and not for human therapeutic use. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
(19R)-13-Deoxy-19-hydroxyenmein is an enmein-type diterpene derivative with anti-proliferative activity. It is the parent compound of enmein-type diterpene analogs and can be used in the preparation of antitumor drugs. The compound has molecular formula C₂₀H₂₆O₆ and molecular weight 362.42. No clinical trials or regulatory approvals exist. For research use only.
|
| Molecular Formula |
C20H26O6
|
|---|---|
| Molecular Weight |
362.417
|
| Exact Mass |
362.172
|
| CAS # |
16763-48-7
|
| PubChem CID |
44632005
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
26
|
| Complexity |
728
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC1(CC[C@H]2[C@]3([C@@H]1[C@@H](OC3)O)[C@@H]4CC[C@@H]5[C@H]([C@]4(C(=O)C5=C)C(=O)O2)O)C
|
| InChi Key |
CTIGXMGFKDJDRU-QLVGEYSLSA-N
|
| InChi Code |
InChI=1S/C20H26O6/c1-9-10-4-5-11-19-8-25-16(23)13(19)18(2,3)7-6-12(19)26-17(24)20(11,14(9)21)15(10)22/h10-13,15-16,22-23H,1,4-8H2,2-3H3/t10-,11-,12-,13+,15+,16+,19+,20-/m0/s1
|
| Chemical Name |
(1R,4S,8R,9R,12S,13S,16S,19R)-9,19-dihydroxy-7,7-dimethyl-17-methylidene-3,10-dioxapentacyclo[14.2.1.01,13.04,12.08,12]nonadecane-2,18-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7592 mL | 13.7961 mL | 27.5923 mL | |
| 5 mM | 0.5518 mL | 2.7592 mL | 5.5185 mL | |
| 10 mM | 0.2759 mL | 1.3796 mL | 2.7592 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
